CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Romidepsindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01353664
NCT01353664Phase 2Completed
CompareCT.gov

An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols

Celgene·interventional·Posted May 16, 2011·Updated Nov 25, 2019

In Brief

A Phase 2 clinical trial evaluating Romidepsin for Lymphoma and Cancer. Completed, enrolled 19 participants across 3 sites in 2 countries.

Detailed Summary

This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Cancer
CountriesUnited Kingdom, United States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 16, 2011
Enrollment StartMay 1, 2011
Primary CompletionSep 5, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.1 years ago

Interventions

Romidepsindrug

The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.